Every Form 4 that Envoy Medical (COCH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow COCH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full COCH filings page.
Envoy Medical, Inc. (COCH) reported that officer Robert Potashnick, CAO & VP of Finance, received a grant of 250,000 stock options on 2026-08-24 with an exercise price of $0.746 per share, expiring on 2036-08-24. According to the vesting terms, options to purchase 62,500 shares vest on 2027-08-24 and the remaining 187,500 shares vest pro rata on the 24th of each month thereafter for 36 months.
Potashnick also has an existing option covering 15,000 underlying shares at a $0.53 exercise price, plus direct holdings of 212,500 shares of Class A common stock. In addition, he holds warrants exercisable for 127,500 and 212,500 Class A shares at a $0.40 exercise price, which become exercisable upon shareholder approval and have expirations tied to key FDA milestones for Envoy Medical’s Acclaim CI Device.
Envoy Medical, Inc. filed a Form 4 showing that Chief Executive Officer Brent T. Lucas received significant new equity awards tied to regulatory milestones for the company’s Acclaim cochlear implant. On June 19, 2026, he was granted 1,000,000 Restricted Stock Units, each representing one share of Class A Common Stock. These RSUs will vest if the U.S. Food and Drug Administration grants approval (including conditional approval) for the Acclaim cochlear implant during the performance period from June 19, 2026 to June 18, 2030.
On the same date, Lucas was also granted 1,000,000 stock options to buy Class A Common Stock at an exercise price of $0.634 per share, expiring on June 19, 2036. The filing also lists his existing equity exposure, including 329,946 Class A Common shares held directly and multiple warrants and options with exercise prices ranging from $0.40 to $11.50 per share, which together show a substantial stake linked to the company’s long-term performance.
Envoy Medical, Inc. Chief Executive Officer Brent T. Lucas reported an acquisition of 32,856 shares of Class A Common Stock at $0.599 per share. These shares were acquired under the company’s Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(d) and Rule 16b-3(c). Following this grant, he directly holds 329,946 common shares.
Lucas also reports significant derivative positions. He holds warrants covering 62,500 and 37,500 underlying shares at an exercise price of $0.40 per share, and additional warrants for 110,987 shares at $11.50 per share expiring on September 29, 2028. Certain warrants become exercisable only upon shareholder approval of the underlying share issuance, and Series A-1 and A-2 warrants can expire earlier upon specified FDA-related milestones for the Acclaim CI Device.
In stock options, Lucas holds rights to buy 200,000 shares at $0.53 per share expiring on February 5, 2036, and 879,749 shares at $2.40 per share expiring on October 15, 2033. Footnotes describe vesting schedules for option blocks of 659,811 and 219,938 shares starting on October 15, 2023, and for blocks of 50,000 and 150,000 shares starting on February 5, 2027, with monthly pro rata vesting thereafter.
Envoy Medical, Inc. director Chas McKhann received a grant of stock options covering 100,000 shares of Class A common stock. The options have an exercise price of $0.72 per share and expire on April 15, 2036.
Beginning May 15, 2026, these options vest pro rata on the 15th of each month over 36 consecutive months. After this grant, McKhann holds stock options for 100,000 underlying shares directly.
Patel Mona Chetan reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 812,500 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 187,500 shares.
Potashnick Robert reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 552,500 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 127,500 shares.
Kantor Susan reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 249,990 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 57,690 shares.
BRYNELSEN CHARLES reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 2,600,000 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 600,000 shares.
Lucas Brent T. reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 162,500 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 37,500 shares.
TAYLOR GLEN A reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 48,750,000 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 11,250,000 shares.
Envoy Medical, Inc. reported that Interim CFO Robert Potashnick received a grant of stock options on February 5, 2026. The award covers 15,000 options to purchase Class A common stock at an exercise price of $0.53 per share, held directly.
The vesting schedule is structured so that 3,750 options vest on February 5, 2027, with the remaining 11,250 options vesting pro rata on the 5th of each month over the following 36 months. This aligns the Interim CFO’s compensation with longer-term company performance.
Envoy Medical, Inc. Chief Executive Officer Brent T. Lucas reported a new stock option grant. On 02/05/2026, he received 200,000 stock options to buy Class A Common Stock at an exercise price of $0.53 per share, granted at no cost.
According to the vesting schedule, options to purchase 50,000 shares vest on 02/05/2027, and 150,000 additional shares vest pro rata on the 5th of each month thereafter for 36 consecutive months. Following this grant, he holds 234,590 Class A Common shares, 879,749 previously granted stock options, and 110,987 warrants, all held directly.
Envoy Medical, Inc. director Mona Chetan Patel reported changes in her holdings on a Form 4. On 12/03/2025 she acquired 25,000 stock options, each with an exercise price of $0.813, exercisable starting 05/01/2026 and expiring 12/03/2035, covering 25,000 shares of Class A common stock. She also beneficially owns 20,000 shares of Class A common stock directly and holds 25,000 stock options with a $2.4 exercise price expiring 10/15/2033. The filing notes that options to purchase 6,250 shares vest on 10/15/2024, with the remaining 18,750 shares vesting pro rata on the 15th of each month for 36 months.